X

Clinical Trials

Contact Us

Breast Cancer

A011801

The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib


A191901

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions


EA1181 (CompassHER2-pCR)

Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)


EAZ171 (Paclitaxel Arm Closed 6/4/21)

Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women


URCC 18007

Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue


S1714

A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients


NRG BR004 (Temporarily Suspended to Accrual)

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer


S1706

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer


S1703

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer


URCC 16070 (Temporarily Suspended)

Treatment of Refractory Nausea